医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
23期
123-124
,共2页
左炔诺孕酮宫内缓释系统%子宫腺肌病
左炔諾孕酮宮內緩釋繫統%子宮腺肌病
좌결낙잉동궁내완석계통%자궁선기병
LNG-IUS%Adenomyosis%Levonorgestrel
目的探讨释放左炔诺孕酮宫内缓释系统(曼月乐)治疗子宫腺肌病的疗效和安全性。方法对50例子宫腺肌病患者放置左炔诺孕酮宫内缓释系统后进行12个月的随访。在放置前，放置后1、2、4、6、12个月时分析患者痛经程度，月经量，子宫内膜厚度、血清CA125的变化。结果放置左炔诺孕酮宫内节育器后患者痛经明显缓解，月经量明显减少，子宫内膜变薄(P<0.01)，子宫体积略缩小，血清CA125有下降。结论对子宫腺肌瘤的治疗安全有效，是一种较理想的保守性治疗手段。
目的探討釋放左炔諾孕酮宮內緩釋繫統(曼月樂)治療子宮腺肌病的療效和安全性。方法對50例子宮腺肌病患者放置左炔諾孕酮宮內緩釋繫統後進行12箇月的隨訪。在放置前，放置後1、2、4、6、12箇月時分析患者痛經程度，月經量，子宮內膜厚度、血清CA125的變化。結果放置左炔諾孕酮宮內節育器後患者痛經明顯緩解，月經量明顯減少，子宮內膜變薄(P<0.01)，子宮體積略縮小，血清CA125有下降。結論對子宮腺肌瘤的治療安全有效，是一種較理想的保守性治療手段。
목적탐토석방좌결낙잉동궁내완석계통(만월악)치료자궁선기병적료효화안전성。방법대50례자궁선기병환자방치좌결낙잉동궁내완석계통후진행12개월적수방。재방치전，방치후1、2、4、6、12개월시분석환자통경정도，월경량，자궁내막후도、혈청CA125적변화。결과방치좌결낙잉동궁내절육기후환자통경명현완해，월경량명현감소，자궁내막변박(P<0.01)，자궁체적략축소，혈청CA125유하강。결론대자궁선기류적치료안전유효，시일충교이상적보수성치료수단。
Objective: to study the release is the left's progesterone palace slow-release system (mann month music) treatment of uterine gland myopathy efficacy and safety. Methods: 50 cases of patients with uterine gland myopathy place left is progesterone palace's slow release system after 12 months of fol ow-up. Placed in front, put 1, 2, 4, 6, 1 2 months analysis patients dysmenorrhea degree, menstrual quantity, endometrial thickness, serum CA125 changes. Results: the left's place is progesterone intrauterine device with dysmenorrhea significant relief, the menstrual quantity significantly reduced, endometrial thin (P < 0.01), uterine bulk slightly narrowed, serum CA125 have dropped. Conclusion: in the treatment of uterine fibroids gland is safe and effective, is a kind of ideal conservative treatment.
